PM

Paul McKenzie

Dr McKenzie has more than 30 years of leadership experience in the global biotechnology industry, including managing complex organizations. Prior to joining CSL, Dr McKenzie was executive vice president of Pharmaceutical Operations & Technology at Biogen. He also served in a range of senior level roles in R&D and manufacturing at Johnson & Johnson, Bristol Myers Squibb and Merck. He is a Member of the Innovation and Development Committee.

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
10/02/26N/A27,354N/AN/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
29/10/25
Issued
58,360$170.770$9,966,137As advised by the company
01/09/25
Sell
3,699$208.814$772,402On-market trade
01/09/25
Expiry
13,261$210.270$2,788,390As advised by the company
01/09/25
Exercise
8,101$210.270$1,703,397Conversion of securities
01/09/25
Issued
8,101$210.270$1,703,397Conversion of securities